

THE FOLLOWING IS AN ENGLISH TRANSLATION PREPARED FOR THE CONVENIENCE OF THE SHAREHOLDERS AND INVESTORS. THE OFFICIAL TEXT IN JAPANESE OF THE NOTICE OF RESOLUTIONS AT THE ORDINARY GENERAL MEETING OF SHAREHOLDERS HAS BEEN PREPARED IN ACCORDANCE WITH STATUTORY PROVISIONS AND MAILED TO THE RESPECTIVE SHAREHOLDERS SEPARATELY. SHOULD THERE BE ANY INCONSISTENCY BETWEEN THE TRANSLATION AND THE OFFICIAL TEXT IN TERMS OF THE CONTENTS OF THE NOTICE, THE LATTER SHALL PREVAIL. THE COMPANY ACCEPTS NO LIABILITY FOR ANY MISUNDERSTANDING CAUSED BY THE TRANSLATION FOR ANY REASON WHATSOEVER.

Securities code: 6869

June 25, 2010

Notice of Resolutions at the 43rd Ordinary General Meeting of Shareholders

Dear Shareholders:

We would hereby like to inform you that the following items were reported and resolved at the 43rd Ordinary General Meeting of Shareholders held today.

Yours faithfully,

Hisashi Ietsugu, President & CEO
SYSMEX CORPORATION
1-5-1 Wakinohama-Kaigandori,
Chuo-ku, Kobe, Hyogo Prefecture
651-0073, Japan

Items reported:

1. **The Business Report, the Consolidated Financial Statements for the 43rd Fiscal Year (from April 1, 2009 to March 31, 2010), as well as the Auditing Reports on the Consolidated Financial Statements by the Accounting Auditors and by the Board of Corporate Auditors.**
2. **The Non-consolidated Financial Statements for the 43rd Fiscal Year (from April 1, 2009 to March 31, 2010)**

We reported on the contents of the above-mentioned Business Report, the Consolidated Financial Statements, the Non-consolidated Financial Statements, and the results of the audits on the Consolidated Financial Statements by the Accounting Auditors and the Board of Corporate Auditors.

Items resolved:

Bill No. 1:

Appropriation of Surplus

This bill was approved and passed as proposed, thus the year-end dividend was set at 31 yen per share.

Bill No. 2:

Partial Amendment to the Articles of Incorporation

This bill was approved and passed as proposed.

The details of amendment are as follows:

(Underlined text represents changes)

Before Amendments	After Amendments
<p style="text-align: center;">CHAPTER I GENERAL PROVISIONS</p> <p>Article 1. (Omitted)</p> <p>(Purpose)</p> <p>Article 2. The purpose of the Company shall be to engage in the following businesses:</p> <ol style="list-style-type: none">1. Research, manufacture and sale of medical equipment;2. Research, manufacture and sale of measuring instruments and physical and chemical appliances;3. Research, manufacture and sale of communications/information processing equipment;4. Research, manufacture and sale of medicines, quasi-medicines, reagents, chemicals, industrial chemicals, poisonous substances, hazardous substances and agricultural chemicals;5. Research, manufacture and sale of nursing care instrument and appliances and nursing care goods;6. Scientific testing relating to medical care;7. Publication and sale of medical -related books;8. Research, guidance and management of health care exercising facility and its utilization; <p style="text-align: center;">(Newly established)</p> <p><u>9.</u> Sale of software, technology and information related to the preceding items;</p> <p style="text-align: center;">(Newly established)</p> <p><u>10.</u>Exports and imports of products described in items 1, 2, 3, 4, 5, 7 and <u>9</u> above;</p> <p><u>11.</u>Lease of products described in items 1, 2, 3, 5 and <u>9</u> above;</p>	<p style="text-align: center;">CHAPTER I GENERAL PROVISIONS</p> <p>Article 1. (Same as the current provision)</p> <p>(Purpose)</p> <p>Article 2. The purpose of the Company shall be to engage in the following businesses:</p> <ol style="list-style-type: none">1. Research, manufacture and sale of medical equipment;2. Research, manufacture and sale of measuring instruments and physical and chemical appliances;3. Research, manufacture and sale of communications/information processing equipment;4. Research, manufacture and sale of medicines, quasi-medicines, reagents, chemicals, industrial chemicals, poisonous substances, hazardous substances and agricultural chemicals;5. Research, manufacture and sale of nursing care instrument and appliances and nursing care goods;6. Scientific testing relating to medical care;7. Publication and sale of medical -related books;8. Research, guidance and management of health care exercising facility and its utilization;<u>9. Telecommunications business, information service, advertising and system operation service based on communication network;</u><u>10.</u>Sale of software, technology and information related to the preceding items;<u>11.Medical-related information and consulting services;</u><u>12.</u>Exports and imports of products described in items 1, 2, 3, 4, 5, 7 and <u>10</u> above;<u>13.</u>Lease of products described in items 1, 2, 3, 5 and <u>10</u> above;

Before Amendments	After Amendments
<p><u>12.</u>Contract for inspection and maintenance of products described in items 1, 2, 3, 5 and <u>9</u> above;</p> <p><u>13.</u>Planning, supervision and contract for installation work related to items 1, 2, 3 and 5 above;</p> <p><u>14.</u>General leasing;</p> <p><u>15.</u>Sale, purchase, lease and management of real estate;</p> <p><u>16.</u>Investment in the businesses related to each of the preceding items; and</p> <p><u>17.</u>Any business incidental to each of the preceding items</p> <p>Article 3. ~ Article 44. (Omitted)</p>	<p><u>14.</u>Contract for inspection and maintenance of products described in items 1, 2, 3, 5 and <u>10</u> above;</p> <p><u>15.</u>Planning, supervision and contract for installation work related to items 1, 2, 3 and 5 above;</p> <p><u>16.</u>General leasing;</p> <p><u>17.</u>Sale, purchase, lease and management of real estate;</p> <p><u>18.</u>Investment in the businesses related to each of the preceding items; and</p> <p><u>19.</u>Any business incidental to each of the preceding items</p> <p>Article 3. ~ Article 44. (Same as the current provision)</p>

Bill No. 3:**Election of One (1) Corporate Auditor**

As proposed, the one (1) candidate Hiromu Fujioka was elected as Corporate Auditor and he assumed his office.

The Directors, Corporate Auditors and Officers as of June 25, 2010 are as follows:

Representative Director, President and CEO	Hisashi Ietsugu	Full-time Corporate Auditor	Haruyoshi Kobayashi
Director and Senior Managing Officer	Kenichi Yukimoto	Full-time Corporate Auditor	Toshiyuki Miyauchi
Director and Managing Officer	Masayoshi Hayashi	Corporate Auditor	Hiromu Fujioka
Director and Managing Officer	Shigenori Ohigashi	Corporate Auditor	Isamu Inamasu
Director and Managing Officer	Yukio Nakajima	Executive Officer	Takuji Nishino
Director and Managing Officer	Koji Tamura	Executive Officer	Katsuo Uhara
Director and Executive Officer	Kazuya Obe	Executive Officer	Masami Kitagawa
Director and Executive Officer	Mitsuru Watanabe	Executive Officer	Michiaki Ishida
		Executive Officer	Yukio Hamaguchi
		Executive Officer	Takashi Goda
		Executive Officer	Kaoru Asano

Payment of the Year-End Dividend

1. Please receive the year-end dividend for the 43rd fiscal year in accordance with the instructions shown on the reverse side of the enclosed “Year-End Dividend Warrant for the 43rd Fiscal Year”
2. For shareholders who have designated a bank account to which the dividends shall be remitted, please confirm the enclosed “Statement of Year-End Dividend for the 43rd Fiscal Year” and “Confirmation of Designated Account for the Payment of Dividends.”